logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Severe Pain

    Medications for Severe Pain

    FiltersReset Filters
    22 results

    • belbuca

      (buprenorphine hydrochloride)
      BioDelivery Sciences International Inc
      Usage: BELBUCA is indicated for the management of severe and persistent pain requiring long-term opioid treatment when alternative options are inadequate. It is not recommended for as-needed use and should be reserved for patients for whom other treatments have failed or are unsuitable.

    • buprenorphine

      (Buprenorphine)
      Amneal Pharmaceuticals NY LLC
      Usage: Buprenorphine transdermal system is indicated for managing severe, persistent pain requiring long-term opioid treatment when alternative options are insufficient. It is not suitable for as-needed analgesic use and is reserved for patients who cannot tolerate or achieve adequate pain control with other treatments due to risks of addiction and overdose.

    • buprenorphine hydrochloride

      (Buprenorphine Hydrochloride)
      ENDO USA, Inc.
      Usage: Buprenorphine hydrochloride injection is indicated for managing severe pain requiring an opioid analgesic when alternative treatments are inadequate. It should be reserved for patients who cannot tolerate non-opioid options or when those options fail to provide sufficient pain relief.

    • buprenorphine hydrochloride

      (Buprenorphine Hydrochloride)
      Hospira, Inc.
      Usage: Buprenorphine hydrochloride injection is indicated for managing severe pain that requires an opioid analgesic when alternative treatments are inadequate. It is reserved for cases where non-opioid options are intolerable or ineffective, and should not be used long-term unless pain severity persists.

    • butorphanol tartrate

      (Butorphanol Tartrate)
      Hikma Pharmaceuticals USA Inc.
      Usage: Butorphanol Tartrate Nasal Spray is indicated for managing severe pain requiring opioid analgesics when alternative treatments are inadequate. It should be used with caution due to risks of addiction, abuse, and misuse, and only when other pain relief options have failed or are intolerable.

    • duramorph

      (morphine sulfate)
      Hikma Pharmaceuticals USA Inc.
      Usage: DURAMORPH is indicated for managing severe pain requiring opioid analgesics via intravenous, epidural, or intrathecal administration, when alternative treatments have proven inadequate. It is not for continuous microinfusion devices and should be reserved for patients who cannot tolerate or achieve adequate relief with non-opioid options.

    • fentanyl

      (FENTANYL)
      Mylan Pharmaceuticals Inc.
      Usage: The fentanyl transdermal system is indicated for managing severe, persistent pain in opioid-tolerant patients requiring long-term opioid treatment when other options are inadequate. It is not intended for as-needed use and carries risks of addiction, abuse, and overdose.

    • fentanyl system

      (Fentanyl)
      ALVOGEN
      Usage: Fentanyl transdermal system is indicated for managing severe, persistent pain in opioid-tolerant patients requiring long-term opioid therapy, when other treatments are insufficient. It is not meant for as-needed use. Caution is advised due to risks of addiction, abuse, and overdose.

    • hydromorphone hydrochloride

      (Hydromorphone Hydrochloride)
      Trigen Laboratories, LLC
      Usage: Hydromorphone hydrochloride extended-release tablets are indicated for managing severe, persistent pain requiring long-term opioid treatment when alternative options are inadequate. They are not intended for as-needed use and are reserved for opioid-tolerant patients due to risks of addiction, abuse, and overdose.

    • hydromorphone hydrochloride

      (hydromorphone hydrochloride)
      Padagis US LLC
      Usage: Hydromorphone hydrochloride extended-release tablets are indicated for managing severe, persistent pain requiring long-term opioid treatment when alternative therapies are inadequate. They should not be used as needed and are reserved for opioid-tolerant patients due to risks of addiction, abuse, and overdose.